Insider · CIK 0001760648

OrbiMed Capital GP VII LLC

CIK 0001760648 Name as filed on the most recent filing

Filed as OrbiMed Capital GP VII LLC (63)

188 transaction lines · from 63 filings · filed 2018-12-13 to 2026-06-24 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-06-22 S, Open-market sale Enliven Therapeutics, Inc.ELVN 4 lines 39,014,046, disposed Open Form 4 filing 0000947871-26-000653
2026-06-15 S, Open-market sale Enliven Therapeutics, Inc.ELVN 2 lines 12,668,988, disposed Open Form 4 filing 0000947871-26-000637
2026-05-28 P, Open-market purchase Q32 Bio Inc.QTTB 2 lines 15,000,000, acquired Open Form 4 filing 0000947871-26-000593
2025-06-26 S, Open-market sale Passage BIO, Inc.PASG 70,375, disposed Open Form 4 filing 0000947871-25-000629
2025-06-25 S, Open-market sale Passage BIO, Inc.PASG 45,804, disposed Open Form 4 filing 0000947871-25-000629
2025-06-24 S, Open-market sale Passage BIO, Inc.PASG 81,060, disposed Open Form 4 filing 0000947871-25-000629
2025-04-24 S, Open-market sale Passage BIO, Inc.PASG 21,822, disposed Open Form 4 filing 0000947871-25-000423
2025-04-23 S, Open-market sale Passage BIO, Inc.PASG 30,372, disposed Open Form 4 filing 0000947871-25-000423
2025-04-22 S, Open-market sale Passage BIO, Inc.PASG 26,537, disposed Open Form 4 filing 0000947871-25-000423
2025-04-17 S, Open-market sale Passage BIO, Inc.PASG 25,440, disposed Open Form 4 filing 0000947871-25-000415
2025-04-16 S, Open-market sale Passage BIO, Inc.PASG 20,341, disposed Open Form 4 filing 0000947871-25-000415
2025-04-15 S, Open-market sale Passage BIO, Inc.PASG 3,924, disposed Open Form 4 filing 0000947871-25-000415
2025-02-18 P, Open-market purchase MBX Biosciences, Inc.MBX 2 lines 1,551,963, acquired Open Form 4 filing 0000947871-25-000199
2025-02-14 P, Open-market purchase MBX Biosciences, Inc.MBX 2 lines 468,793, acquired Open Form 4 filing 0000947871-25-000199
2025-01-14 S, Open-market sale Passage BIO, Inc.PASG 47,414, disposed Open Form 4 filing 0000947871-25-000034
2025-01-13 S, Open-market sale Passage BIO, Inc.PASG 11,511, disposed Open Form 4 filing 0000947871-25-000034
2025-01-10 S, Open-market sale Passage BIO, Inc.PASG 83,298, disposed Open Form 4 filing 0000947871-25-000034
2025-01-08 S, Open-market sale Passage BIO, Inc.PASG 51,005, disposed Open Form 4 filing 0000947871-25-000021
2025-01-07 S, Open-market sale Passage BIO, Inc.PASG 37,301, disposed Open Form 4 filing 0000947871-25-000021
2025-01-06 S, Open-market sale Passage BIO, Inc.PASG 15,000, disposed Open Form 4 filing 0000947871-25-000021
2024-12-20 S, Open-market sale Passage BIO, Inc.PASG 138,193, disposed Open Form 4 filing 0000947871-24-001037
2024-12-11 S, Open-market sale Passage BIO, Inc.PASG 64, disposed Open Form 4 filing 0000947871-24-000998
2024-12-10 S, Open-market sale Passage BIO, Inc.PASG 6,412, disposed Open Form 4 filing 0000947871-24-000998
2024-12-09 S, Open-market sale Passage BIO, Inc.PASG 45,512, disposed Open Form 4 filing 0000947871-24-000998
2024-12-06 S, Open-market sale Passage BIO, Inc.PASG 17,140, disposed Open Form 4 filing 0000947871-24-000995
2024-12-04 S, Open-market sale Passage BIO, Inc.PASG 60,198, disposed Open Form 4 filing 0000947871-24-000995
2024-09-19 S, Open-market sale Passage BIO, Inc.PASG 27,903, disposed Open Form 4 filing 0000947871-24-000769
2024-09-18 S, Open-market sale Passage BIO, Inc.PASG 18,711, disposed Open Form 4 filing 0000947871-24-000763
2024-09-17 S, Open-market sale Passage BIO, Inc.PASG 81,322, disposed Open Form 4 filing 0000947871-24-000763
2024-09-16 S, Open-market sale Passage BIO, Inc.PASG 46,694, disposed Open Form 4 filing 0000947871-24-000763
2024-09-16 P, Open-market purchase MBX Biosciences, Inc.MBX 2 lines 12,000,000, acquired Open Form 4 filing 0000950170-24-107538
2024-08-13 S, Open-market sale Keros Therapeutics, Inc.KROS 2 lines 11,002,500, disposed Open Form 4 filing 0000947871-24-000702
2024-07-16 S, Open-market sale Terns Pharmaceuticals, Inc.TERN 3 lines 51,880, disposed Open Form 4 filing 0000947871-24-000627
2024-07-15 S, Open-market sale Terns Pharmaceuticals, Inc.TERN 3 lines 509,760, disposed Open Form 4 filing 0000947871-24-000627
2024-05-16 S, Open-market sale Enliven Therapeutics, Inc.ELVN 2 lines 22,877,262, disposed Open Form 4 filing 0000947871-24-000500
2023-08-15 S, Open-market sale Galecto, Inc.GLTO 401,651, disposed Open Form 4 filing 0000947871-23-000873

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. OrbiMed Capital GP VII LLC, insider transactions. Retrieved 2026-08-24 from https://ebomi.com/insider/0001760648

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.